203 related articles for article (PubMed ID: 36054729)
1. Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.
Wat M; Mollanazar NK; Ellebrecht CT; Forrestel A; Elenitsas R; Chu EY
J Cutan Pathol; 2022 Nov; 49(11):978-987. PubMed ID: 36054729
[TBL] [Abstract][Full Text] [Related]
2. Lichen Planus Pemphigoides Associated With PD-1 and PD-L1 Inhibitors: A Case Series and Review of the Literature.
Boyle MM; Ashi S; Puiu T; Reimer D; Sokumbi O; Soltani K; Onajin O
Am J Dermatopathol; 2022 May; 44(5):360-367. PubMed ID: 35120032
[TBL] [Abstract][Full Text] [Related]
3. Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy.
Liu SS; Howard T; Fattah YH; Adams A; Hanly AJ; Karai LJ
Am J Dermatopathol; 2023 Apr; 45(4):246-249. PubMed ID: 36825932
[TBL] [Abstract][Full Text] [Related]
4. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
Sugawara A; Koga H; Abe T; Ishii N; Nakama T
J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
[TBL] [Abstract][Full Text] [Related]
6. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.
Shah RR; Bhate C; Hernandez A; Ho CH
Dermatol Ther; 2022 May; 35(5):e15432. PubMed ID: 35266258
[TBL] [Abstract][Full Text] [Related]
7. Challenges and pitfalls between lichen planus pemphigoides and bullous lichen planus.
Papara C; Danescu S; Sitaru C; Baican A
Australas J Dermatol; 2022 May; 63(2):165-171. PubMed ID: 35196400
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma.
Kwon CW; Murthy RK; Kudchadkar R; Stoff BK
JAAD Case Rep; 2020 Oct; 6(10):1045-1047. PubMed ID: 32995442
[No Abstract] [Full Text] [Related]
10. Pembrolizumab-Induced Lichen Planus Pemphigoides in a Patient with Metastatic Adrenocortical Cancer: A Case Report and Literature Review.
Madan V; Marchitto MC; Sunshine JC
Dermatopathology (Basel); 2023 Aug; 10(3):244-258. PubMed ID: 37606485
[TBL] [Abstract][Full Text] [Related]
11. Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review.
Combemale L; Bohelay G; Sitbon IY; Ahouach B; Alexandre M; Martin A; Pascal F; Soued I; Doan S; Morin F; Grootenboer-Mignot S; Caux F; Prost-Squarcioni C; Le Roux-Villet C
Front Immunol; 2024; 15():1243566. PubMed ID: 38686381
[TBL] [Abstract][Full Text] [Related]
12. IgG autoantibodies from a lichen planus pemphigoides patient recognize the NC16A domain of the bullous pemphigoid antigen 180.
Skaria M; Salomon D; Jaunin F; Friedli A; Saurat JH; Borradori L
Dermatology; 1999; 199(3):253-5. PubMed ID: 10592407
[TBL] [Abstract][Full Text] [Related]
13. Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.
Hübner F; Langan EA; Recke A
Front Immunol; 2019; 10():1389. PubMed ID: 31312198
[TBL] [Abstract][Full Text] [Related]
14. Lichen planus pemphigoides evolving into pemphigoid nodularis.
Sakuma-Oyama Y; Powell AM; Albert S; Oyama N; Bhogal BS; Black MM
Clin Exp Dermatol; 2003 Nov; 28(6):613-6. PubMed ID: 14616828
[TBL] [Abstract][Full Text] [Related]
15. Lichen Planus Pemphigoides Mimicking Toxic Epidermal Necrolysis.
Ondhia C; Kaur C; Mee J; Natkunarajah J; Singh M
Am J Dermatopathol; 2019 Nov; 41(11):e144-e147. PubMed ID: 31145106
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.
Shirouchi K; Koshikawa S; Shinya K; Watanabe H; Izumi M; Yoshimura K; Sueki H
J Dermatol; 2021 Sep; 48(9):1428-1432. PubMed ID: 34097308
[TBL] [Abstract][Full Text] [Related]
17. Deposition of C3, C9 neoantigen and vitronectin (S-protein of complement) in lichen planus pemphigoides.
Hintner H; Sepp N; Dahlbäck K; Dahlbäck B; Fritsch P; Breathnach SM
Br J Dermatol; 1990 Jul; 123(1):39-47. PubMed ID: 1697188
[TBL] [Abstract][Full Text] [Related]
18. Coexisting lichen planus and bullous pemphigoid or lichen planus pemphigoides?
Lang PG; Maize JC
J Am Acad Dermatol; 1983 Jul; 9(1):133-40. PubMed ID: 6350379
[TBL] [Abstract][Full Text] [Related]
19. Lichen planus pemphigoides is a heterogeneous disease: a report of five cases studied by immunoelectron microscopy.
Bouloc A; Vignon-Pennamen MD; Caux F; Teillac D; Wechsler J; Heller M; Lebbé C; Flageul B; Morel P; Dubertret L; Prost C
Br J Dermatol; 1998 Jun; 138(6):972-80. PubMed ID: 9747357
[TBL] [Abstract][Full Text] [Related]
20. Lichen planus pemphigoides: its relationship to bullous pemphigoid.
Davis AL; Bhogal BS; Whitehead P; Frith P; Murdoch ME; Leigh IM; Wojnarowska F
Br J Dermatol; 1991 Sep; 125(3):263-71. PubMed ID: 1911320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
